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INTRODUCTION
Immunisation of children with Diphtheria, Pertusis and Tetanus is now
universal in most countries of the world and has considerably helped to
diminish the morbidity and mortality from these vaccine preventable diseases.
DIPHTHERIA
Diphtheria is an acute infectious disease caused by cornynebacterium
diphtheriae. It is an ancient disease which used to occur in epidemics and was
associated with high mortality.
Corynebacaterium diphtheriae is an irregularly staining gram positive,
non-motile, nonspore forming, pleomorphic bacillus. The pathogenicity of the
organism is due to the release of exotoxin. Diphtheria toxin is lethal to man in
an amount of about 230µg/kg.
Diphtheria spreads worldwide. The only known reservoir of diphtheria is
human beings.
The disease affects mainly unimmunised children, below 15years of age.
Even though majority of the cases are still reported from developing countries,
over the years its incidence has gone down considerably due to immunization.
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PERTUSIS:
Pertusis is an acute, highly communicable infection of the respiratory
tract caused by Bordetella pertusis. It may affect any susceptible host but is
common and serious in infancy and early childhood. It should be considered
with high index of suspicion in an unimmunised child presenting with severe
spasmodic cough. In India before the introduction of EPI, there were more than
2.5 lacs of cases reported in 1974 and 4.5 lacs in 19781
Mortality in pertusis was around 6 percent 2 . Similar high incidence has
been reported in 1950’s in developed countries, but after the introduction of
vaccine, incidence of pertusis came down significantly. In India during
postvaccination era, there has been a decline in incidence of pertusis.
Epidemics of pertusis are reported every 3 to 4 years in UK. Most recent
estimates of WHO indicate that 12.9 million die of ARI3. Pertusis accounts for
0.26 million of them (6.1 percent of ARI death). It is thus clear, that even with
decline in pertusis after vaccination, it still continues to be a major health
hazard. Infants may be susceptible before the age at which vaccine is
immunogenic, postvaccinal immunity is likely to wane off in older children
who may suffer from mild or modified form of disease that is unrecognizable.
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Of course, unimmunised children in the community continue to suffer and
spread infection.
TETANUS:
Tetanus is an acute illness caused by a soluble exotoxin of the bacterium
clostridium tetani. The name “Tetanus” means arching of the body due to
stiffening, which is a prominent feature of this disease.
Tetanus occurs worldwide and is an important cause of neonatal deaths
in developing countries. The causative organism clostridium tetani is part of
the normal flora in human and animal intestine and is disseminated through the
excreta.
The contamination of the wounds, unhygienic and improper handling of
the umbilical cord in newborns, lack of hygienic habits and aseptic care during
and after delivery in women are the chief risk factors in infection.
According to a WHO report (1992) 112 countries reported a total of
19,882 cases of tetanus of which 15, 394 cases or neonatal tetanus. Of these,
India reported 5915 cases of neonatal tetanus4. The incidence is high in tropical
countries with humid climate. More cases are reported from rural than urban
areas.
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Tetanus usually manifests in a generalized from, but sometimes it may
be local, as seen in children with otits media. Localised tetanus produces pain
and spasm of the muscles in proximity of the site of injury. The fatality rate of
the generalized form of disease is around 10 percent 5
Tetanus neonatorum is usually a serious and often fatal disease. It
usually begins at the age of 3 to 10 days.
DPT VACCINE:
For immunizing infants, the preparation of choice is DPT. Firstly
because, the infant can be immunized simultaneously against three disease viz.,
Diphtheria, pertusis and tetanus, which is a great gain administratively.
Secondly the pertusis component in DPT vaccine enhances the potency of the
diphtheria toxoid.
There are two type of DPT vaccine plain and adsorbed. Adsorption is
usually carried out on a mineral carrier like aluminum phosphate or hydroxide.
Studies have shown that adsorption increases the immunological effectiveness
of the vaccine. The WHO recommends that only adjuvant DPT preparation be
utilized in immunization programmes 6.
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The composition of DPT vaccines in India is shown in table:
Contents Glaxo Kasuli
Diphtheria toxoid 25Lf 30Lf
Tetanus toxoid 5Lf 10Lf
Pertusis (millions) 20,000 32,000
Aluminium phosphate 2.5mg 3mg
Thiomersal B.P. 0.01% 0.01%
The plain (DPT) vaccine can be used as a booster.
STORAGE:
DPT vaccines should not be frozen. They should be stored in a
refrigerator between +2 to +8 C. The vaccine should be used before the date of
expiry indicated on the vial. When issued to a sub-centre, the vaccine should
be used within a week. The vaccine will lose potency if kept at room
temperature over a longer period of time.
OPTIMUM AGE:
It has been found that young infants respond well to immunization with
potent vaccines and toxoids even in the presence of low to moderate levels of
maternal antibodies. According, the Global advisory group of the EPI, has
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recommended that DPT vaccine can be safely and effectively administered, as
early as 6 weeks after birth 7.
NUMBER OF DOSES:
Three doses of DPT, is considered optimal for primary immunization.
Furthermore, in almost all recipients, three doses of DPT are associated with
higher and more sustained levels of Diphtheria and tetanus antitoxin and
acceptable level of pertusis protection.
INTERVAL BETWEEN DOSES:
The current recommendation is to allow an interval of 4 weeks between
the 3 doses with a booster injection at one and half years, followed by another
booster (DT only) at the age of 5 years. Studies have shown that two months
intervals do not offer any advantage over one month interval for protection
against diphtheria and tetanus and may not enhance pertusis protection.
MODE OF ADMINISTRATION:
All vaccines containing mineral carrier or adjuvants should be injected
deep intramuscular. This applies to DPT also, which may be given in the
anterolateral aspect of the thigh.
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REACTIONS:
Fever and mild local reactions following DPT immunization are
common. It is estimated that 2 to 6% of vaccinese develop fever of 39 C or
higher and that 5 to 10% experience swelling and indurations or pain lasting
more than 48 hours 8
The most severe complications following DPT immunization are
neurological and are thought to be due primarily to the pertusis components of
the vaccine, the estimated risk is 1:170,00 doses administered 9
CONTRAINDICATIONS:
DPT should not be repeated if a severe reaction occurred after a previous
dose. Such reactions include.
1. Collapse or shock like state
2. Persistent screaming episodes
3. Temperature above 40 c
4. Convulsions and other neurological symptoms.
5. Anaphylactic reactions.
Since the severity of pertusis infection decreases with age, the pertusis
component in DPT vaccine is not usually recommended after the age of 5
years.
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Therefore children over the age of 5 years who have not received DPT,
need only 2 doses of DT vaccine 4 weeks apart with a booster dose 6 months to
1 year later.
Those children who received the primary course of DPT earlier, should
receive only DT as a booster at 5 years of age.
For immunizing children over 12 years of age and adults, the preparation
of choice of DT, which is an adult type of diphtheria-tetanus vaccine. This
preparation contains no more than 2 Lf of diphtheria toxoid per dose,
compared with 25 Lf in the ordinary (Pediatric) DPT Vaccines.
Administration of DT vaccine to adults is carried out in 2 doses at an
interval of 4 to 6 weeks followed by a booster 6 to 12 months after the second
dose.
HEPATITIS-B
Ever since the identification of the structure of the Hepatitis-B (HBV)
and the noble prize winning work of characterizing the Hepatitis B surface
(HBsAg), efforts have been on to develop a safe effective vaccine against the
Hepatitis B virus. Through intensive effects of microbiologists,
epidemiologists and clinicians, we are now at the stage where such a vaccine is
available. Hence it is possible to interrupt transmission of this infection,
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resulting in tremendous reduction in morbidity and mortality from the disease
in the long term.
Hepatitis B infection has a usual incubation period ranging from 1-6
months, following which the infected person suffers from loss of appetite,
nausea, vomiting, abdominal pain and Jaundice.
Some individuals remain asymptomatic during the acute infection, very
rarely an infected individual many die of fulamianant hepatitis during the acute
stage, within days or weeks. More commonly, the initial symptomatic or
asymptomatic infection subsides; the individual recovers and develops lifelong
immunity. However, some persons develop chronic infection.
The age of initial infection is a major factor determining the outcome. 10 It has
been noted that fewer than 10% of children below 5 years of age are
symptomatic when they first become infected but 30-50% of them develop
chronic infection later in life.
The figure for chronicity goes as high as 80-90% for infants who get
infected during the first year of life. In contrast, 30-50% of adults are sick
when they first become infected, but only 2-5% develop chronic infection.
Further 15 to 25% of chronically infected persons are likely to die of
hepatocellular carcinoma or cirrhosis in later life. Thus, chronic infection and
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
its sequelea are mostly responsible for the morbidity and mortality caused by
Hepatitis B.
BURDEN OF HEPATITIS B INFECTION IN INDIA:
For any clinical condition, disease burden is calculated on the basis of
the morbidity and mortality caused by the disease. In the case of Hepatitis B, it
may not be possible to calculate morbidity and mortality caused by acute
infection, as many infected persons remain asymptomatic and hence the acute
phase may be missed altogether. Further, mortality during acute infection is not
unduly high, therefore it is not a good reflector of disease burden. Hence a
calculation of disease burden based on these indicators is likely to be
misleading. The real risk of Hepatitis B infection is the risk of long term viral
carriage and replication with the risk of chronicity and it’s complications
including chronic liver disease, cirrhosis, hepatocellular carcinoma and death.
Thus the prevalence of these clinical conditions in a population may indirectly
suggest the burden of HB infection 11
Although exact figures for chronic liver disease, cirrhosis and mortality
due to Hepatitis B infection have not been calculated in India, in population
studies, data generated at referral centers suggests that around 40,000 deaths
annually are attributable to Hepatitis B infection. It has also been estimated
that around 11,000 new cases of Hepatocellular carcinoma occur every year for
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which the hepatitis B virus may be responsible in a large majority. The overall
risk of mortality from various complications of chronic HB infection is about
25%. Applying this figure to the fact that about 4% of India’s population
carries the HBsAg, it translates to one death in every hundred being caused by
Hepatitis B12. Using this calculation Hepatitis B has been categorized as a
significant health problem in India.
Most of the 50 odd Indian studies with varying sample size among
different population group have reported HBsAg prevalence around 2-4%
although it ranges from as low as 0.7% as high as 10%.
Based on the prevalence of HBsAg in the population, the world is
roughly divided into three zones of endemicity. India is categroised in the
intermediate group.
Another newly emerging concept is infection with mutant strains which
can lead to chronicity even in the absence of the surface antigen, such an
infection may be detectable only by finding HBV DNA (i.e.) other markers are
absent. This group is important because
1. They may not be picked up on routine screening.
2. Their numbers are reportedly increasing.
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3. The currently available vaccines may not protect against mutant
infection.
4. A mathematical model recently worked out suggests that owing to
mutations, HBV strains will become resistant to the currently available
vaccine in about 20 years.
As mentioned previously, the earlier the age of initial infection with
HBV, the higher is the risk of developing chronicity. The risk is thus
maximum for babies infected during birth or early infancy.
The results of the various small studies indicates that perinatal
transmission may account for 29-55% of the carrier load in India.
Besides the studies that suggest a rather high incidence of perinatal
transmission, there is another body of evidence that indirectly suggests this
fact, which is the analysis of age specitic HBsAg prevalence. The prevalence
of HBsAg positivity and anti HBsAg in preschool children is either higher or
not significantly different from older children and adolescents, suggesting that
most of the infection has occurred before 5 years of age. The overall
prevalence of carriers in preschool children is 2 to 2.5%. Further age stratified
data shows almost uniform prevalence of HBsAg and antibody from 6 months
onwards, suggesting that most, if not all under 5 children have been infected in
the first half of infancy itself. From this it is reasonable to conclude that, most
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of this infection would have been acquired perinatally, since exposure to HBV
at this age is more likely to have occurred by this route than horizontally. Thus,
perinatal transmission in India is high and is possibly major route of
transmission13
PREVENTION OF HBV INFECTION:
Since chronically infected persons are the main reservoir of HB
infection, strategies for prevention are focused on this group. The WHO has
suggested that three major strategies may be helpful in interrupting
transmission of HBV. These include
1. Routine infant vaccination to prevent child to child transmission.
2. Interruption of perinatal transmission.
3. Vaccination of older age individuals at risk of infection.
This three pronged strategy covers the three high risk groups for HB
infection viz. Newborn babies of infected mothers, children and older persons
at risk.
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HEPATITIS B VACCINE:
There are two types of vaccines against HB infection, which are plasma
derived vaccines and recombinant vaccines.
The former are prepared by purifying plasma of persons with chronic
HBV infection, and using the HBsAg therein . Following the widespread usage
of the vaccine, the number of infected individuals will decease and the
availability of plasma will also dwindle, making its manufacture difficult.
The second type of vaccine is a genetically engineered preparation
where in plasmids containing the genetic material required for the production
of the surface antigen are incorporated into the genetic material of a yeast
(sacchromuyces cerevisiae) which then begin to produce the surface antigen.
The two types of vaccine did not differ significantly in their safety profile,
immunogenicity and sero-efficacy. In recent years the recombinant vaccine has
gained popularity and is almost universally used.
WHO SHOULD BE VACCINATED?:
It is clear that children and even newborn babies are at risk of
contracting HB infection, therefore the best strategy would be to vaccinate all
children including newborn babies, thereby reducing the risk of HB infection at
the earliest possible age.
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Selective immunization to high risk groups like those in the medical
profession, professional blood donars, drug abusers, those engaged in hetero or
homosexual promiscuity is unlikely to interrupt successfully the transmission
of the infection.
Based on these considerations in 1991 the EPI Global Advisory group of
the WHO recommended that HBV vaccine should be integrated into National
Infant Immunisation programs of all countries with a carrier rate of 8% or
greater by 1995 and in all remaining countries by 199714
The immunization committee of IAP also recommended incorporation
of Hepatitis B vaccine into universal infant immunization to the government of
India several years back, although this has been accepted and begun to be
implemented only in recent months.
AT WHAT AGE SHOULD VACCINATION BEGIN?
In a population where perinatal transmission is significant, unless all
pregnant women are screened for HBsAg, it is impossible to predict which
baby is likely to be infected, implying that proportion of newborn babies will
be infected at birth itself. In such a situation, administration of vaccine would
be akin to post exposure prophylaxis, which obviously must be administered as
soon as possible in order to be effective. This is the rational of recommending
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the first dose of vaccine at birth itself, because optimum efficacy is achieved
when the vaccine is given with in the first 24 hours after birth. A delay of even
seven days renders the vaccine ineffective against perinatal transmission of
infection15
SCHEDULE OF IMMUNIZATION:
The latest recommendations of the advisory committee on immunization
practices (ACIP) and the American Academy of family physicians (AAFP)
also specify that the recommended interval between the first and second doses
of Hepatitis B vaccine is 4 weeks. It is also recommended that there should be
a gap of at least 8 weeks between second and third doses, though the interval
could vary form 2 to 17 months.
However such a schedule makes the incorporation and integration of HB
vaccine into existing immunization schedules a cumbersome exercise.
Therefore attempts were made to delay the four weeks dose to six weeks, and
the results have been acceptable. However in order to fully integrate the HB
schedule into the existing schedule, the doses should be administered at one
month interval, along with the DPT vaccine. Trials have shown that giving the
third dose 4 weeks after the second dose results in seroconversion but with a
lower GMT of antibody. But this GMT of antibody is in the protective range
(0.1 Iu-1 Iu)16
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Based on these considerations, the Indian academy of pediatrics
recommended two schedules for infants.
1. The first is to vaccinate babies at birth, 6 weeks and 14 weeks. The
schedule is in agreement outlined earlier and will also be effective
against perinatal transmission.
2. The second option is to give the three doses of HB vaccine at the
same time as DPT namely 6, 10 and 14 weeks.
Obviously, this strategy will not prevent perinatal transmission. This
discrepancy has been explained as a strategy so as not to deprive babies who
miss the birth dose, from getting at least some degree of protection.
It remains debatable whether a strategy that is unlikely to yield
maximum benefit should be pursued at all, particularly in light of the fact that
giving an option of delaying HB vaccine, may make some parents opt for the
later administered schedule. This dual schedule strategy has not been evaluated
in terms of protective efficacy and long term benefits.
COMBINATION VACCINES:
Infectious diseases are the world’s leading cause of death and vaccines
are the most effective tool to combat them. The number of vaccines is
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increasing over the last 15 years. If all these vaccines are included in a active
immunization schedule the number of injections to administer all vaccines are
quite high.
According to children’s vaccine initiative launched in 1990, also the
ideal vaccine would provide all indicated antigens in a single dose and would
be heat stable, effective when administered soon after birth and affordable to
families of all economic levels.
But some studies have shown altered immune responses to various
vaccines when they are given combined with other vaccines, similarly adverse
events after combined vaccine are generally said to be increased 17
COMBINATION VACCINE TYPES:
There are two basic types of combination vaccines:
1. In the first type, multiple different antigens of a microbial agent are
mixed together as single product to confer immunization against the
multiple serotypes of disease causing agent. These include vaccines
against poliomyelitis and pneumococcal disease (capsular
polysaccharide antigens).
2. In other type, multiple different antigens of different pathogens are
mixed together to immunize against different disease such as vaccines
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against Diphtheria, Pertusis and Tetanus. In the further, new design of
combination vaccines,DNA Technology or use of non pathogenic
vectors capable of expressing multiple vaccine antigens.
ISSUES IN COMBINATION VACCINES:
With the increasing availability and use, several important issues need to
be considered to make the best possible use of these vaccines against the
prevention of vaccine preventable diseases.
These are listed below:
1. There should be antigenic compatibility between different antigens.
2. The immunogenic response to each component should be adequate.
3. The product should have a shelf life for a period of 18-24 months.
4. There should be an appropriate timing for the use of each antigen in on
immunization schedules.
5. The side effects should be at an acceptable level. There may be
additional concerns such as difficulties in assessing the vaccine
component in case of an adverse event following immunization.
BENEFITS OF COMBINATION VACCINES:
1. To the child and family:
a. Multiple antigens are given with single injection, reducing number of
injections and total number of visits.
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b. There is reduced parental anxiety and pain to child leading to higher
compliance, low dropout rates.
2. To the health planner:
a. Reduce storage place, packing, handling and transport.
b. Reducing burden on cold chain.
c. Reducing documentation and logistics.
ISSUES CONCERENED WITH COMBINATION VACCINES:
1. IMMUNOGENICITY
The combination of vaccines may produce decreased immunogenicity of
the individual components because of physical interaction among the vaccine
components. For example some studies have shown that addition of Hepatitis
B antigen with DPT, decrease the immunological response to Diphtheria and
Tetanus toxoid. .This may be due to cross interference of antigens in the
combination vaccine 18
The other reason may be due to the combination of one vaccine which is
administered with adjuvant, with another vaccine not given with adjuvant may
lead to the displacement of the adjuvant and the decreased immune response to
first antigen. Additions of stabilizers, buffers and excipients may also interferes
with the compatibility between the difference antigens.
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2. ADVERSE EVENTS
A study done by G. Papaevangelou, et al in Greece have shown that adverse
effects both local and systemic are more frequent in combination vaccine
group (DPT-HB) than separately given DPT and Hepatitis B vaccine. They
have reported that this may be due to the use of adjuvant, stabilizers and
buffers in combination vaccine. (DPT-HB).
3. COST OF THE COMBINATION VACCINE
Cost of the combination vaccine is many a times higher than the individual
formulation. This is a very important factor to be concerned in a developing
country like India.
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REVIEW OF LITERATURE
I. Dr. Yong Poovarawan et al conducted a study comparing the
Immunogenticy and safety between DPT –HB combined vaccine and DPT and
Hepatitis –B given separately.
This study was conducted in Department of Pediatrics, Chulalohgkorn
University and Hospital, Bangkok, Thailand
It was a Randomised control trial with 50 subjects in combined vaccine
group and 50 subjects in separate vaccine group
They assessed the Immunogencity and safety profile between the two
groups.
Their conclusion was that the antibody titre for Diphtheria and Tetanus
was more in the separately given vaccine when compared to combined vaccine
and it was also statistically significant.
The frequency of adverse reactions also was more in the combined
vaccine group when compared to separate vaccine group.
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They concluded that although the combined vaccine has the advantage
of having been given by single injection, the separately given (DPT & HB)
vaccine is more Immunogenic and has a good safety profile.
II. A similar study was conducted by Dr. G. Papavagelou et.al in
Department of Peadiatrics, West Africa Hospital, Athens, Greece.
It was also a Randomised control trial with 60 subjects in combined
vaccine group and 60 subjects in separate vaccine group.
The results of their study showed that antibodies to Diphtheria was more
in separate vaccine group when compared to combined vaccine group but
antibody titres against Pertusis, Tetanus and Hepatitis B was more or less equal
between the two groups with out any statistical significance.
But separate vaccine group got a good safety profile when compared to
combined vaccine group.
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III. A similar study was conducted by a pharmaceutical company in
Lithuanian infants.
In that study about 150 subjects was enrolled .75 subjects Randomised
to combined vaccine group and another 75 subjects Randomised to separate
vaccine group.
They also studied the immunogenicity and safety profile between the
two groups.
They concluded that combined vaccine (DPT-HB) is equally
immunogenic and has a good safety profile comparing to separate vaccine
group.
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STUDY JUSTIFICATION
In our region there is no study comparing the
immunogenicity and safety of DPT-HB combination vaccine
and DPT & Hepatitis-B vaccines given separately. So, in this
study we are going to compare the immunogenicity and
safety between the combination vaccine and vaccines given
separately.
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AIM
The aim of this study is to find out and compare the
Immunogenicity and safety of DPT-HB combination vaccine
and DPT & Hepatitis B vaccines given separately.
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MATERIALS AND METHODS
STUDY DESIGN : Randomised Control Trial.
STUDY PLACE : Immunisation Clinic,
Institute of Child Health & Hospital for
Children.
STUDY PERIOD : March 2005 to March 2006.
STUDY POPULATION : Infants at 6-8 weeks of age brought to
Immunisation Clinic.
SAMPLE SIZE : 60.
SAMPLING TECHNIQUE : Simple random.
INCLUSION CRITERIA
Full term, Normal healthy infants at 6-8 weeks of age.
EXCLUSION CRITERIA
Previous vaccination or infection with DPT.
Administration of Immunoglobulims, or any other blood products since
birth.
Major congenital or Hereditary immuno deficiency.
Those who have not given consent.
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MANEUVER
After getting consent from the parents the subjects will be allocated in each
group with the use of a standard table of Randomisation. Peripheral venous
blood of 2 ml is withdrawn, centrifuged and the serum will be stored in deep
freezer at 20 Celsius.
The serum will be sent to the laboratory for Pre-vaccination titre evaluation.
After 3 doses of vaccination, Postvaccination sample will be withdrawn 3 to
6 weeks after the last dose. The serum will be sent to the laboratory for
Postvaccination titre evaluation.
A diary card will be issued to the subject after each dose of vaccination.
The parent or guardian will be asked to note any adverse effects both local
and systemic, in the Diary Card. And they will be asked to reproduce the Dairy
card during the next visit.
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SCHEDULE OF VISITS AND OBSERVATIONS
Visit/
Procedures
Visit 1 Visit 2 Visit 3 Visit 4
Visit
Intervals
6-8 weeks
after birth
(1st dose)
4-6 weeks
after 1st dose
4-6 weeks after
2nd dose
3-6 weeks
after 3rd dose.
Written
informed
consent
ü - - -
Eligibility
Criteria ü - -
-
Vaccination ü ü ü
-
Blood
Sampling ü - - -
Assessment
of local &
systemic
reactions
ü ü ü ü
Diary cards
provided ü ü ü
-
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DETAILED DESCRIPTION OF STUDY VISITS
Visit –1
6- 8 weeks after birth.
General Physical examination.
Informed consent form signed by legally acceptable representative.
Blood sampling for estimation of antibodies.
First dose of vaccine.
Assessment of local and systemic adverse reactions for the initial 30
minuteso one hour at the study hospital.
Give dairy card 1 to the subject with instruction.
Visit –2
Collect dairy card 1.
Check for any exclusion criterion.
Second dose of vaccine.
Local and systemic adverse reaction evaluation for the initial 30 minutes
to one hour at the study hospital.
Give diary card 2 to the subject with instruction.
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Visit –3
Collect diary card 2.
Check for any exclusion criterion.
Third dose of vaccine.
Local and systemic adverse reaction evaluation for first 30 minutes to
one hour.
Give diary card 3 to the subject with instruction.
Visit –4
Collect diary card 3.
Local and systemic adverse reaction evaluation.
General physical examination.
Blood sampling for estimation of antibodies.
IMMUNOGENICITY
Blood samples for the estimation of antibody titers will be collected
before and three to six weeks after the third dose. The antibodies estimated will
be Anti –Diphtheria (IgG-ELISA NOVOTEC),Anti-pertusis(Ig G ELISA
NOVOTEC),Anti-tetanus(IgG ELISA NOVOTEC) and AntiHBsAg ELISA.
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SAFETY
Local and systemic adverse affects will be mentioned after each dose.
Close monitoring for 30 minutes to 1 hour after each dose.
Both solicited and unsolicited local and systemic reactions will be
recorded on the diary card by the parent till the next dose.
All subjects will be followed up for local and systemic reactions even
after 30 days after the 3rd dose of vaccine.
PREMATURE TERMINATION
Subjects will be withdrawn from the study and referred for appropriate
care in the following cases,
1) Any clinical adverse event, intercurrent illness or other medical
condition which indicates to the investigator that continued
participation is not in the best interest of the subject.
2) The subjects will be withdrawn in case of any serious adverse
events.
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ADVERSE EVENT REPORTING
ADVERSE EVENTS:
Any untoward medical occurrence in a subject or clinical investigation
subject during the administration of a pharmaceutical product and which does
not necessarily have to have a causal relationship with this treatment.
LOCAL REACTIONS
A local reaction is defined as the occurrence of one or several reactions
at the injection site within 28 days following vaccination. Local reactions are
- Local Pain
- Swelling
- Redness at Injection Site
- Induration
- Unsolicited local reaction.
SYSTEMIC REACTIONS
A systemic event is defined as the occurrence of one or several of the
following symptoms within 28 days following vaccination. They are:
- Fever
- Persistent Cry
- Unusual Crying for more than 60 minutes
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- Vomiting
- Diarrhea
- Loss of appetitie
- Restlessness
COMPOSITION
Dose of Individual Components in the combined and separate vaccines:
Active Ingredients Per Dose
Diphtheria : 25 Lf
Tatanus : 5 Lf
Pertusis : 15 U
Hepatitis B : 10 micorgrams
Other Ingredients
Thiomersal - 0.025 mg
Aluminium hydroxide - 0.625 mg
MODE OF ADMININSTRATION
Deep Intramuscular injections in the anterolateral thigh.
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DOSAGE
Three doses (0.5 ml / dose) will be administered (WHO guidelines)
Separate vaccine group:-
Visits Age Separate Vaccine
1 6 Weeks DPT & HB Separately
2 10 Weeks DPT & HB Separately
3 14 Weeks DPT & HB Separately
Combined vaccine group:-
Visits Age Combined Vaccine
1 6 Weeks DPT –HB
2 10 Weeks DPT –HB
3 14 Weeks DPT – HB
STORAGE CONDITION
The vaccine vials will be kept in a refrigerator at +2 to + 8 Cwith a lock.
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STATISTICAL CONSIDERATION
ANALYSIS OF IMMUNOGENICITY
Analysis of Immunogencity will be evaluated by estimation of antibody
titers to Diphtheria, Pertusis, tetanus and Hepatitis B.
Geometric mean titre of antibodies against Diphtheria, Pertusis, tetanus
and HBsAg will be calculated then.
The recommended antibody titre for protection for each antigen according
to WHO are:
Antigens Safe protection Long term protection
Diphtheria 0.1 to 1.0 Iu /ml >1.0 Iu/ml
Pertusis - >11 NT units/ml
Tetanus 1 to 5 Iu/ml >5 Iu/ml
HBsAg - >10 mIu/ml
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ANALYSIS OF SAFETY
Number of subjects experiencing local and systemic reactions during
follow up period.
Number of serious adverse events occurring during the follow up period.
Number and percentage of subjects with at least one local, systemic and
any adverse event after vaccination and during the 4 weeks follow up
period.
Number and percentage of subjects with atleast one serious adverse
event, with the frequencies of each type of event.
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OBSERVATION
THE FOLLOWING TABLE SHOWS THE PRE-VACINATION
ANTIBODY TITRE IN THE COMBINED VACCINE GROUP:
Subject
Initial Subject ID
Diphtheria
Iu/ml
Pertusis
NT Units/ml
Tetanus
IU/ml
Anti HBsAg
mIU /ml
BOU 01 .05 5 5 3
BON 02 .05 4 3.16 2
KA1 03 .05 1 2.28 2.5
RAH 04 .04 2 1.52 1.46
THA 05 .35 2.5 1.7 1.5
ARU 06 0.24 3.6 0.26 2.6
SAT 07 0.95 9.03 3.34 107
DIN 08 .01 5.1 4.5 1.76
MOH 09 .02 4.5 2.58 4.82
CHA 110 .04 3.6 1.8 1.05
BOJ 11 .03 3.8 1.9 2.05
HAR 12 .01 4.8 1.46 3.07
VIJ 13 .05 51.1 1.46 4.5
DEV 14 0.3 1.2 1.42 1.07
MAD 15 .06 2.4 2.88 1.76
SAL 16 .04 117 1.76 1.81
BOV 17 .03 4 3.74 2.8
SIV 18 .02 3 2.7 1.56
KAN 19 .05 1 2.24 1.4
BOA 20 .01 117 .05 1.6
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Continued…
PRE 21 .05 0.4 4.5 2.6
BOL 22 .04 4.5 3.48 2.1
YUV 23 .025 3.6 1.74 3.45
REN 24 .035 3.1 1.7 4.4
NIV 26 0.28 3.2 1.11 9.72
YOG 27 0.28 3.2 1.98 2.5
BOP 29 .012 51.1 2.2 .01
SHY 30 .45 4.5 2.29 1.5
1)Diphtheria 3 )Tetanus
0.1 to 1.0 Iu/ml : Safe Protection 0.1 to 1.0 Iu/ml : Safe Protection
>1.0 Iu/ml : Long term protection >1 Iu/ml : Long term Protection
2)Pertusis 4) Anti HBsAg
<9 NT Units/ml : Negative < 10 mIu / ml : No Protection
9 to 11 NT Units/ml : Borderline >10 mIu /ml : Safe Protection.
> 11 NT Units /ml: Positive
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GEOMETRIC MEAN TITRE OF ANTIBODIES IN PRE VACCINATION
SUBJECTS IN THE COMBINED VACCINE GROUP:
Diphtheria : .07 Iu /ml
Pertusis : 6.3 NT units /ml
Tetanus : 1.8 Iu/ml
Anti H Bs Ag : 5.2 mIU/ml
INTERPRETATION
The geometric mean antibody titre for Diphtheria and tetanus are already
in the protective range but the antibodies to pertusis and Hepatitis B are not
in the protective range.
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THE FOLLOWING TABLE SHOWS THE PRE-VACCINATION
ANTIBODY TITRE IN THE SEPARATE VACCINE GROUP:
Subject
Initial Subject ID
Diphtheria
Iu/ml
Pertusis
NT
Units/ml
Tetanus
IU/ml
AntiHBsAg
mIU /ml
BOA 01 .02 17.5 1.7 9.71
VAN 02 .39 7.82 3.22 15.3
BON 03 0.71 16.9 0.5 6.44
SHA 04 .01 18.3 0.62 4.51
LOG 05 .04 15.4 2.3 2.5
KOW 06 .01 11.7 1.62 2.1
HAR 07 .04 25.2 4.72 3.0
BOK 08 00 11.5 1.84 4.24
SEN 09 .05 18 2.73 3.4
GEE 10 .43 21.4 1.84 9.71
BOM 11 .01 15.8 2.73 3.4
ABU 12 0.71 11.7 2.2 2.8
PRA 13 0.39 16.9 0.62 8.8
KAV 15 .02 7.82 0.3 4.56
ALA 16 .04 17.5 1.84 87.3
SRA 17 0.05 18 3.22 6.44
BMB 18 .04 11.7 1.7 3.4
MAM 19 .39 21.4 0.62 9.80
RAJ 20 .02 18 0.5 8.70
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Continued…
BOR 21 .01 18 2.73 2.5
SHO 22 .04 11.5 1.84 2.6
SAB 23 .05 25.2 4.72 20.4
BOS 24 .04 11.7 2.3 4.51
DIV 25 .01 15.4 1.62 6.44
MAH 26 0.71 18.3 2.2 4.24
DIN 27 0.39 16.9 1.52 15.3
THA 28 .02 7.82 .62 87.3
ASW 29 .02 16.7 0.3 9.84
CHA 30 .04 17.5 0.5 9.71
1)Diphtheria 3 )Tetanus
0.1 to 1.0 Iu/ml : Safe Protection 0.1 to 1.0 Iu/ml : Safe Protection
>1.0 Iu/ml : Long term protection >1 Iu/ml : Long term Protection
2) Pertusis 4) Anti HBsAg
<9 NT Units /ml : Negative < 10 mIu / ml : No Protection
9 to 11 NT Units /ml : Borderline >10 mIu /ml : Safe Protection
> 11 NT Units/ml : Positive
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GEOMETRIC MEAN TITRE OF ANTIBODIES IN PREVACCINATION
SUBJECTS IN THE SEPARATE VACCINE GROUP:-
Diphtheria - .04 Iu/ml
Pertusis - 9 NT units / ml
Tetanus - 1.5 Iu/ml
Anti HBsAg - 7.5 Iu/ml
Interpretation
The geometric mean antibody titre to Diphtheria and Tetanus are in the
protective range but the antibodies to pertusis and Hepartitis B are not in the
protective range.
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THE FOLLOWING TABLE SHOWS THE POSTVACCINATION
ANTIBODY TITRE IN THE COMBINED VACCINE GROUP:
Subject
Initial Subject ID
Diphtheria
Iu/ml
Pertusis
NT
Units/ml
Tetanus
IU/ml
Anti HBsAg
mIU /ml
BOU 01 .08 56.3 3.1 813
BON 02 .15 46.3 1.64 854
KAI 03 1.88 58.5 2.16 1285
RAH 04 1.01 28.5 .23 198
THA 05 ,64 64.9 7.38 34.2
ARU 06 .53 46 .68 93.8
SAT 07 1.10 30.4 1.64 975
DIN 08 .48 35.7 .34 1004
MOH 09 .87 50.1 1.44 1094
CHA 10 .57 60.5 2.36 495
BOJ 11 10.5 49.9 4.26 36.6
HAR 12 0.52 52.9 2.43 750
VIJ 13 <.05 35.9 3.25 690
DEV 14 .31 36.9 2.42 875
MAD 15 .82 60.6 1.52 883
SAL 16 .64 54.5 1.76 180
BOV 17 .54 55.1 1.24 598
SIV 18 1.04 42.7 6.50 168
KAN 19 .39 43.5 0.27 422
BOA 20 .85 31.5 1.72 1846
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Continued…
PRE 21 0.59 36.2 1.3 31.4
BOL 22 0.20 64.4 1.7 393
YUV 23 0.44 33.8 1.64 48.8
REN 24 0.25 51.9 1.46 1710
THL 25 <05 59.7 0.39 737
YOG 27 0.54 62 1.98 203
VIN 28 0.53 64.9 0.54 532
BOP 29 .09 66.1 1.98 692
SHY 30 .24 27.9 1.84 195
1)Diphtheria 3 )Tetanus
0.1 to 1.0 Iu/ml : Safe Protection 0.1 to 1.0 Iu/ml : Safe Protection
>1.0 Iu/ml : Long term protection >1 Iu/ml : Long term Protection
2) Pertusis 4) Anti HBsAg
<9 NT Units /ml : Negative < 10 mIu / ml : No Protection
9 to 11 NT Units /ml : Borderline >10 mIu /ml : Safe Protection
> 11 NT Units/ml : Positive
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GEOMETRIC MEAN TITRE OF ANTIBODIES IN POSTVACCINATION
SUBJECTS IN THE COMBINED VACCINE GROUP:-
Diphtheria : 0.4 /Iu ml
Pertusis : 46.7 NT units /ml
Tetanus : 1.5 Iu/ml
Anti H BsAg : 403. 4 Iu/ml
Interpretation
The geometric mean antibody titre to all the antigens in the combined
vaccine group after 3 doses of vaccination are in the protective range
according to WHO criteria.
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THE FOLLOWING TABLE SHOWS THE POST VACCINATION
ANTIBODY TITRE IN THE SEPARATE VACCINE GROUP:-
Subject
Initial
Subject ID
Diphtheria
Iu/ml
Pertusis
NT
Units /ml
Tetanus
IU/ml
Anti HBsAg
mIU /ml
BOA 01 0.74 51.8 1.52 244
VAN 02 0.52 68 4.04 257
BON 03 1.74 83 2.22 65.8
SHA 04 .86 126.3 7.14 219
LOG 05 3.76 66.4 1.62 577
KOW 06 1.16 93.2 2.16 60.4
HAR 07 0.54 46.3 1.42 100
BOK 08 1.15 19.2 2.9 411
SEN 09 .96 31.8 1.93 637
GEE 10 1.69 38.7 1.36 557
BOM 11 .41 35.7 1.36 557
ABU 12 1.67 60 4.23 369
PRA 13 .23 45.7 1.52 396
PRS 14 .84 34.5 2.24 1424
KAV 15 1.64 54 2.24 57.1
ALA 16 .55 30.3 1.9 869
SRA 17 .21 28. 2.02 1251
BMB 18 0.3 63.8 1.68 216
MAM 19 1,87 10.2 4.88 4.16
RAJ 20 1.04 41.1 2.7 52.2
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Continued…
BOR 21 1.8 49.8 8,54 496
SHO 22 .39 9.75 2.59 728
SAB 23 .67 64.2 1.6 267
BOS 24 ,63 67.4 7.84 138
DIV 25 0.4 43.8 2.44 677
MAH 26 1.27 67 1.3 197
DIN 27 .49 44.6 2.36 683
THA 28 .26 38 1.36 78.4
ASW 29 .28 35 1.46 77.2
CHA 30 1.1 81.8 2.36 241
Only one subject in the separate vaccine group is not seroconverted for
Hepatitis B surface antigen.
1) Diphtheria 3 )Tetanus
0.1 to 1.0 Iu/ml : Safe Protection 0.1 to 1.0 Iu/ml : Safe Protection
>1.0 Iu/ml : Long term protection >1 Iu/ml : Long term Protection
2) Pertusis 4) Anti HBsAg
<9 NT Units /ml : Negative < 10 mIu / ml : No Protection
9 to 11 NT Units /ml : Borderline >10 mIu /ml : Safe Protection
> 11 NT Units/ml : Positive
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GEOMETRIC MEAN TITRE OF ANTIBODIES IN POST VACCINATION
SUBJECTS IN THE SEPARATE VACCINE GROUPS:-
Diphtheria : 0.8 Iu/m
Pertusis : 44.6 NT units /ml
Tetanus : 2.4 IU/ml
AntiHBsAg : 221.3 Iu/ml
INTERPRETATION
The geometric mean antibody titre to all the antigens in separate vaccine
group after 3 doses of vaccination are in the protective range according to
WHO criteria.
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COMPARISON OF GEOMETRIC MEAN TITRE OF ANTIBODIES
BETWEEN COMBINED AND SEPARATE VACCINE GROUPS IN POST
VACCINATION SUBJECTS.
Antibodies
Combined
Vaccine
Separate
vaccine
Statistical
Significance
(P Value)
Diphtheria 0.4 0.8 .02
Pertusis 46.7 44.6 0.81
Tetanus 1.5 2.4 0.04
Anti HBsAg 403.4 221.3 0.05
(P<05:- Statistically Significant)
Though the antibody titres against Diphtheria, Pertusis, Tetanus and
Hepatitis –B of both combined and separate vaccine group are in the protective
range, the Geometric mean titre of antibodies for Diphtheria and Tetanus is
better in separate vaccine group when compared to combined vaccine group
and it is also statistically significant.
The antibody titre for Hepatitis B antigen in the combined vaccine group
is better when compared to separate vaccine group but it is not significant
statistically.
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ADVERSE EFFECTS
Local Swelling, Redness, Fever, Unusual Cry & Irritability are the
commonest adverse effects noticed in both combined and separate vaccine
groups.
VISIT –1
Adverse effects Combined
vaccine (30)
separate vaccine
(30)
statistical
significance
Local redness 22 15 0.06
Local Swelling 10 6 0.24
Fever 8 4 0.20
Unsual Crying 5 3 0.45
Irritability 1 0 0.31
Though adverse effects ( local & systemic) are more common in the
combined vaccine group when compared to separate vaccine group there is no
statistical significance between them.
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VISIT – 2
Adverse effects Combined
vaccine (30)
Separate
vaccine (30) Statistical significance
Local redness 18 12 0.05
Local Swelling 12 7 0.17
Fever 9 6 0.17
Unsual Crying 4 2 0.39
Irritability - - -
There is no statistical significance in the adverse effects between the
combined and separate vaccine groups after the second dose of vaccination.
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VISIT-3
ADVERSE
EFFECTS
COMBINED
VACCINE (30)
SEPARATE
VACCINE (30)
STATISTICAL
SIGNFICANE
Local redness 16 12 0.30
Local Swelling 11 8 0.41
Fever 6 4 0.49
Unsual Crying 5 2 0.23
Irritability 2 2 0.55
Similarly ,after third dose of vaccination, the frequency of adverse
effects are more in the combined vaccine group when compared to separate
vaccine group but statistically it is not significant.
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CONCLUSION
The frequency of adverse effects is more in the combined vaccine group
when compared to separate vaccine group, but it is not significant
statistically.
The Antibody titre for Diphtheria, Pertusis, Tetanus and Hepatitis B of
both combined and separate vaccine groups are in the protective range.
The Immunogenicity for Diphtheria and Tetanus toxoid in the
separate vaccine group is better when compared to combined vaccine
group and it is also statistically significant.
The clinical relevance and long term protection of these subjects needs
further evaluation.
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